Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. The company's lead product candidate, ZN-c5, is a novel, oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor-positive (ER+) / human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Zentalis is also developing ZN-c3, an oral selective estrogen receptor modulator (SERM) for the treatment of ER+/HER2- breast cancer, and ZN-d5, an oral WEE1 inhibitor for the treatment of advanced solid tumors. The company was founded in 2014 and is headquartered in New York, NY.